Gene therapy for hemophilia Authors: Peter J Lenting, Sylvia Fong Published: 2024 Concept Gene therapy with adeno-associated virus (AAV) vectors treats hemophilia A or B by delivering a functional F8 or F9 gene to hepatocytes. This single infusion enables endogenous production of factor VIII (FVIII) or FIX protein, reducing bleeding in patients (Figure) A single infusion of AAV-particles containing cDNA encoding factor VIII or factor IX allows for production of these proteins in hepatocytes, resulting in long-term bleeding protection in hemophilia A or B. Evolution Long-term clinical studies have provided insight into the efficacy, safety, and durability of AAV-mediated gene therapies for hemophilia A1,2 and B.3, 4, 5 Gene therapies have now been approved for hemophilia A (valoctocogene roxaparvovec) and hemophilia B (etranacogene dezaparvovec and fidanacogene elaparvovec) in select regions. Application The approved gene therapies are associated with a significant reduction in bleeding tendency and increased FVIII or FIX activity levels, without the need for additional FVIII or FIX replacement therapies, in the vast majority of patients.3,6 Future steps Improvements in AAV technology, protein expression, and immunogenicity may make AAV-mediated gene therapies more efficient, longer lasting, and safer for people with hemophilia A or B. Conflict-of-interest disclosure P.J.L. receives research funding to institute from BioMarin, Sanofi, Sobi, and Roche. S.F. is employee of BioMarin Pharmaceutical Inc. Acknowledgments Authorship Contribution: P.J.L. and S.F. designed the figure and wrote the manuscript. References